Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis
Introduction: High-dose trivalent, inactivated, split-virus influenza vaccine (IIV3-HD) has been available in the US since 2009 for adults aged ≥ 65 years. To better understand how IIV3-HD provides improved protection against influenza, we systematically reviewed clinical studies comparing immune re...
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
Taylor & Francis Group
2019-03-01
|
| Серии: | Expert Review of Vaccines |
| Предметы: | |
| Online-ссылка: | http://dx.doi.org/10.1080/14760584.2019.1575734 |